GlobeNewsWire · CAR · November 11, 2026

Tempest Therapeutics Exercises Option to License Senlang's CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate

Get the app for more

Explore stock news, insights and company research.